September 14, 2006

BioMimetic Therapeutics’ Clinical Investigators to Receive Award from American Academy of Periodontology for Outstanding Publication

Clinical Investigators to Present Data at Annual AAP Meeting

Franklin, Tenn. – September 14, 2006 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that Company president and CEO, Dr. Samuel E. Lynch, along with his co-authors, will be honored with the prestigious American Academy of Periodontology’s R. Earl Robinson Regeneration Award for the scientific publication they authored entitled Platelet-derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain: Results of a Large Multicenter Randomized Controlled Trial. The publication details the positive results of the pivotal trial for the Company’s lead product GEM 21S®, which was approved by the FDA in November 2005 for the treatment of periodontal disease and gingival recession. The award will be presented at the 92nd Annual Meeting of the American Academy of Periodontology (AAP) in San Diego, CA on Saturday, September 16, 2006.

The R. Earl Robinson Regeneration Award was established by Dr. R. Earl Robinson to encourage research in periodontal regeneration. It is presented to the author(s) of the peer-reviewed published paper that has contributed most to the knowledge of periodontal regeneration in a given calendar year. Dr. Lynch’s co-authors on the article include Myron Nevins, DDS, William V. Giannobile, DDS, Michael K. McGuire, DDS, Richard T. Kao, DDS, James T. Mellonig, DDS, James E. Hinrichs, DDS, Bradley S. McAllister, DDS, Kevin G. Murphy, DDS, Pamela K. McClain, DDS, Marc L. Nevins, DMD, David W. Paquette, DMD, Thomas J. Han, DDS, Michael S. Reddy, DMD, Phillip T. Lavin, PhD, and Robert J. Genco, DDS all of whom were investigators in the pivotal clinical study to evaluate GEM 21S. The award will be accepted at the AAP’s opening ceremony by Dr. Myron Nevins, senior investigator and lead author of the paper.

“I am honored that our paper, based on the scientific rigor and positive results of the GEM 21S pivotal clinical trial, was chosen to receive such an esteemed award,” said Dr. Lynch. “Recognition by a preeminent organization such as the American Academy of Periodontology helps validate the scientific integrity and potential clinical impact of GEM 21S, and its main component rhPDGF, one of the key wound healing stimulators in the body. Moreover, the observation that GEM 21S stimulated bone regeneration in the periodontal study suggests the potential for positive results in our ongoing orthopedic clinical trials and will help pave the way for future approvals for PDGF based product candidates currently under development.”

Additionally, clinical investigators for the GEM 21S pivotal trial will be presenting at six forums during the AAP Annual Meeting highlighted by two General Session presentations. Dr. William Giannobile, who will present at the General Session on Monday, September 18, will provide long-term 12 and 24 month follow up data from the GEM 21S pivotal trial. Dr. Michael McGuire, who will present at the General Session on Tuesday, September 19, will discuss clinical case studies demonstrating the use of PDGF for gingival recession.

About BioMimetic Therapeutics
BioMimetic Therapeutics, Inc. is developing and commercializing bio-active drug-device combination products for the healing of musculoskeletal injuries and disease, including periodontal, orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. Additionally, BioMimetic has clinical trials ongoing for orthopedic bone healing indications. The Company's product and product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration.

Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of BioMimetic. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. There are many important factors that could cause actual results to differ materially from those indicated in the forward-looking statements. BioMimetic’s actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with the marketing of BioMimetic’s product and product candidates, unproven preclinical and clinical development activities, regulatory oversight, and other risks detailed in the company's filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Prospectus dated May 12, 2006, filed with the Securities and Exchange Commission on May 12, 2006 and in the second quarter 2006 10Q dated August 9, 2006. Except as required by law, BioMimetic undertakes no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for changes made to this document by wire services or Internet services.

For further information, visit or contact Kearstin Patterson, manager corporate communications, at 615-236-4419.